Lorna Leal

3.7k total citations
42 papers, 648 citations indexed

About

Lorna Leal is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Lorna Leal has authored 42 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Virology, 22 papers in Infectious Diseases and 13 papers in Epidemiology. Recurrent topics in Lorna Leal's work include HIV Research and Treatment (30 papers), HIV/AIDS Research and Interventions (17 papers) and HIV/AIDS drug development and treatment (13 papers). Lorna Leal is often cited by papers focused on HIV Research and Treatment (30 papers), HIV/AIDS Research and Interventions (17 papers) and HIV/AIDS drug development and treatment (13 papers). Lorna Leal collaborates with scholars based in Spain, United States and Netherlands. Lorna Leal's co-authors include Felipe García, Montserrat Plana, Berta Torres, Josep M. Gatell, Alexy Inciarte, Josep Mallolas, Agathe León, Maria Martínez‐Rebollar, Beatriz Mothe and Alberto C. Guardo and has published in prestigious journals such as Journal of Clinical Investigation, PLoS ONE and The Journal of Urology.

In The Last Decade

Lorna Leal

40 papers receiving 632 citations

Peers

Countries citing papers authored by Lorna Leal

Since Specialization

Citations

This map shows the geographic impact of Lorna Leal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorna Leal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorna Leal more than expected).

Fields of papers citing papers by Lorna Leal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorna Leal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorna Leal. The network helps show where Lorna Leal may publish in the future.

Co-authorship network of co-authors of Lorna Leal

This figure shows the co-authorship network connecting the top 25 collaborators of Lorna Leal. A scholar is included among the top collaborators of Lorna Leal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorna Leal. Lorna Leal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Aplicaciones de la Inteligencia Artificial en Microbiología Agroambiental 2024 ·(unknown), (unknown), Lorna Leal	0
2	The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses 2023 ·Vaccines ·(unknown), Lorna Leal, Carmen Gómez, (unknown), Elena Aurrecoechea, (unknown), Berta Torres, Alexy Inciarte, Beatriz Perdiguero, Mariano Estéban, Felipe García, Montserrat Plana	6
3	Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals 2021 ·Vaccines ·Csaba Fehér, (unknown), Lorna Leal, Montserrat Plana, Mireia Arnedo, Henk‐Jan van den Ham, Arno C. Andeweg, Rob A. Gruters, Francisco Díez‐Fuertes, José Alcamı́, Patrick Aloy, Felipe García	2
4	Recreational Drug Use in People Living with HIV in Spain: Factors Associated with Drug Use and the Impact on Clinical Outcomes 2021 ·AIDS and Behavior ·(unknown), Noé Garín, Ángeles Jaén, José L. Casado, Lorna Leal, (unknown), María José Fuster‐RuizdeApodaca	3
5	Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen 2021 ·Vaccines ·Carmen Gómez, Beatriz Perdiguero, (unknown), Laura Marcos-Villar, (unknown), Lorna Leal, Carlos Óscar S. Sorzano, (unknown), Montserrat Plana, Felipe García, Mariano Estéban	17
6	Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected Individuals 2021 ·Nutrients ·(unknown), (unknown), (unknown), Sonsoles Sánchez‐Palomino, Francisco Díez‐Fuertes, Rosa Casas, (unknown), Sara Castro‐Barquero, (unknown), Irene Fernández, Lorna Leal, José M. Benito, Marc Noguera-Julián, Roger Paredes, Norma Rallón, Ramón Estruch, David Torrents, Felipe García	17
7	Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine 2021 ·Vaccines ·(unknown), Francisco Díez‐Fuertes, Sonsoles Sánchez‐Palomino, José Alcamı́, Montserrat Plana, David Torrents, Lorna Leal, Felipe García	11
8	Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial 2021 ·Frontiers in Immunology ·Lorna Leal, (unknown), Sonsoles Sánchez‐Palomino, Núria Climent, Irene Fernández, (unknown), Yolanda Romero, (unknown), María J. Maleno, Blanca Paño, Judit Pich, Carlos Nicolau, José María Gatell, Montserrat Plana, Felipe García, (unknown)	8
9	Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response 2020 ·Vaccines ·Lorna Leal, Csaba Fehér, (unknown), Berta Torres, Felipe García	13
10	Extremely low viral reservoir in treated chronically HIV-1-infected individuals 2020 ·EBioMedicine ·Cristina Gálvez, Víctor Urrea, Judith Dalmau, (unknown), Bonaventura Clotet, Valérie Monceaux, Nicolas Huot, Lorna Leal, (unknown), María González‐Cao, Michaela Müller‐Trutwin, Asier Sáez‐Cirión, Felipe García, Julià Blanco, Javier Martínez‐Picado, María Salgado	18
11	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix 2019 ·Vaccines ·(unknown), Lorna Leal, Jozefien Buyze, Pieter Pannus, Alberto C. Guardo, María Salgado, Beatriz Mothe, José Moltó, Sara Morón‐López, Cristina Gálvez, Éric Florence, Guido Vanham, Eric C. M. Van Gorp, Christian Brander, Sabine Allard, Kris Thielemans, Javier Martínez‐Picado, Montserrat Plana, Felipe García, Rob A. Gruters	30
12	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection 2018 ·AIDS ·Lorna Leal, Alberto C. Guardo, Sara Morón‐López, María Salgado, Beatriz Mothe, Carlo Heirman, Pieter Pannus, Guido Vanham, Henk‐Jan van den Ham, Rob A. Gruters, Arno C. Andeweg, Sonja Van Meirvenne, Judit Pich, Joan Albert Arnáiz, Josep M. Gatell, Christian Brander, Kris Thielemans, Javier Martínez‐Picado, Montserrat Plana, Felipe García	75
13	Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients 2017 ·AIDS ·(unknown), Montserrat Plana, Alberto C. Guardo, Cristina Andrés, Núria Climent, Teresa Gallart, Lorna Leal, Josep M. Gatell, Sonsoles Sánchez‐Palomino, Felipe García	13
14	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection 2016 ·Journal of Antimicrobial Chemotherapy ·Lorna Leal, Agathe León, Berta Torres, Alexy Inciarte, (unknown), Josep Mallolas, Montserrat Laguno, Maria Martínez‐Rebollar, Ana González-Cordón, Christian Manzardo, Jhon Rojas, Judit Pich, Joan Albert Arnáiz, Josep M. Gatell, Felipe García	11
15	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Case–Control Study 2016 ·AIDS Research and Human Retroviruses ·Lorna Leal, Berta Torres, Agathe León, (unknown), Alexy Inciarte, Vicens Díaz-Brito, Elisa de Lazzari, José María Gatell, Felipe García	4
16	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection 2016 ·Journal of Antimicrobial Chemotherapy ·Lorna Leal, Agathe León, Berta Torres, Alexy Inciarte, (unknown), Josep Mallolas, Montserrat Laguno, Maria Martínez‐Rebollar, Ana González-Cordón, Christian Manzardo, Jhon Rojas, Judit Pich, Joan Albert Arnáiz, Josep M. Gatell, Felipe García	17
17	Neonatal withdrawal syndrome after chronic maternal consumption of 4-methylethcathinone 2014 ·Forensic Science International ·Simona Pichini, Maria Concetta Rotolo, (unknown), (unknown), Lorna Leal, Óscar García‐Algar, Roberta Pacifici	27
18	Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation 2014 ·Journal of the International AIDS Society ·Berta Torres, Alberto C. Guardo, Lorna Leal, Agathe León, (unknown), Miriam J. Álvarez-Martínez, Miguel J. Martínez, Jordi Vilà, Maria Martínez‐Rebollar, Ana González-Cordón, Josep M. Gatell, Montserrat Plana, Felipe García	13
19	Rate and Predictors of Non-AIDS Events in a Cohort of HIV-Infected Patients with a CD4 T Cell Count Above 500 Cells/mm ³ 2013 ·AIDS Research and Human Retroviruses ·(unknown), Berta Torres, Agathe León, Marta Calvo, Lorna Leal, Iñaki Pérez, Montserrat Plana, Mireia Arnedo, Josep Mallolas, Josep M. Gatell, Felipe García	37
20	Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial 2013 ·AIDS Research and Human Retroviruses ·Berta Torres, Norma Rallón, Montserrat Loncà, Alba Díaz, Llúcia Alós, Estebán Martínez, Anna Cruceta, Joan Albert Arnáiz, Lorna Leal, (unknown), Agathe León, Marcelo Sánchez, Eugènia Negredo, Bonaventura Clotet, José M. Gatell, José M. Benito, Felipe García	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact